Athens Research/Cambio - Excellence in Molecular Biology/2 bags of 125 filters only/AP-2002022

价格
面议
货号:AP-2002022
浏览量:59
品牌:Athens Research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Protein Purification

Protein Purification: Apollo 20 mL Ultrafiltration

Apollo ultrafiltration devices are used for purification, concentration or desalting of proteins and viral gene vector particles. They are available in 7 mL and 20 mL versions, each having 3 different membrane retention ratings: 9 kDa, 20 kDa, and 150 kDa.

  • Catalogue
  • Description
  • Protocols
  • References

APOLLO 20 mL CONCENTRATORS

Ultrafiltration using Apollo® Concentrators (US patents 6,269,957, 6,357,601) combines the highest recovery of regenerated cellulose membrane devices with faster concentration of protein samples and viral gene vectors than possible with recent high-speed devices of comparable retention.Apollo ultrafiltration devices are used for purification, concentration or desalting of proteins and viral gene vector particles. They are available in 7 mL and 20 mL versions, each having 3 different membrane retention ratings: 9 kDa, 20 kDa, and 150 kDa.

Orbital Biosciences

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
  • €
AP-2000904009 kDa APOLLO 20 mL CONCENTRATORS1 bag of 8 filters, tubes and caps£70.00QuantityAdd to Order
AP-2000922009 kDa APOLLO 20 mL CONCENTRATORS2 bags of 125 filters onlyPOAQuantityAdd to Order
AP-2000942009 kDa APOLLO 20 mL CONCENTRATORS1 bag of 100 filters only£711.00QuantityAdd to Order
AP-2002004020 kDaAPOLLO 20 mL CONCENTRATOR1 bag of 8 filters, tubes and caps£70.00QuantityAdd to Order
AP-2002010020 kDaAPOLLO 20 mL CONCENTRATOR1 rack of 25 filters, tubes and caps£216.00QuantityAdd to Order
AP-2002022020 kDaAPOLLO 20 mL CONCENTRATOR2 bags of 125 filters onlyPOAQuantityAdd to Order
AP-2002042020 kDaAPOLLO 20 mL CONCENTRATOR1 bag of 100 filters only£711.00QuantityAdd to Order
AP-2015004150 kDaAPOLLO 20 mL CONCENTRATOR1 bag of 8 filters, tubes and caps£70.00QuantityAdd to Order
AP-2015010150 kDaAPOLLO 20 mL CONCENTRATOR1 rack of 25 filters, tubes and caps£216.00QuantityAdd to Order
AP-2015022150 kDaAPOLLO 20 mL CONCENTRATOR2 bags of 125 filters onlyPOAQuantityAdd to Order
AP-2015042150 kDaAPOLLO 20 mL CONCENTRATOR1 bag of 100 filters only£711.00QuantityAdd to Order

APOLLO 20 mL CONCENTRATORS

Ultrafiltration using Apollo® Concentrators (US patents 6,269,957, 6,357,601) combines the highest recovery of regenerated cellulose membrane devices with faster concentration of protein samples and viral gene vectors than possible with recent high-speed devices of comparable retention.Apollo ultrafiltration devices are used for purification, concentration or desalting of proteins and viral gene vector particles. They are available in 7 mL and 20 mL versions, each having 3 different membrane retention ratings: 9 kDa, 20 kDa, and 150 kDa.

Orbital Biosciences

Apollo 20 mL High-Performance Concentrators

with Accelerated Conical Focusing

Use these centrifugal ultra filtration devices with combined simplicity, speed, capacity and recovery for quantitative concentration, purification and separation of proteins and viral gene vectors. Their unique truncated conical filtration chambers provide a high ratio of membrane area to sample size. This, in turn, provides a high degree of concentration in a single spin as well as better control of polarization and fouling at the membrane surface. Apollo has the largest available sample volumes for a given centrifuge tube size

  • >90% quantitative recovery of micrograms of retained protein
  • Quantative salt/buffer exchange in a single spin. 1000x plusconcentration factor capability
  • Fast concentration of up to 20mL of protein or virus sample
  • Biosafety No aerosol generation or air locking
  • No need for hand contact with wet surfaces
  • No invert spin required

click here for more details

Click here for a list of Apollo Citations

Available in packs of 8, 25,100 and 250.

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

APOLLO 20 mL CONCENTRATORS

Ultrafiltration using Apollo® Concentrators (US patents 6,269,957, 6,357,601) combines the highest recovery of regenerated cellulose membrane devices with faster concentration of protein samples and viral gene vectors than possible with recent high-speed devices of comparable retention.Apollo ultrafiltration devices are used for purification, concentration or desalting of proteins and viral gene vector particles. They are available in 7 mL and 20 mL versions, each having 3 different membrane retention ratings: 9 kDa, 20 kDa, and 150 kDa.

Orbital Biosciences

Click here to download protocol

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

APOLLO 20 mL CONCENTRATORS

Ultrafiltration using Apollo® Concentrators (US patents 6,269,957, 6,357,601) combines the highest recovery of regenerated cellulose membrane devices with faster concentration of protein samples and viral gene vectors than possible with recent high-speed devices of comparable retention.Apollo ultrafiltration devices are used for purification, concentration or desalting of proteins and viral gene vector particles. They are available in 7 mL and 20 mL versions, each having 3 different membrane retention ratings: 9 kDa, 20 kDa, and 150 kDa.

Orbital Biosciences

Examples of recent publications citing the use of Orbital Biosciences" Apollo concentrators:

Boss IW, Nadeau PE, Abbott JR, Yang Y, Mergia A, Renne R. A Kaposi"s sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2Rγnull mice. J Virol. 2011 85:9877-86.

DiMattia MA, Nam HJ, Van Vliet K, Mitchell M, Bennett A, Gurda BL, McKenna R, Olson NH, Sinkovits RS, Potter M, Byrne BJ, Aslanidi G, Zolotukhin S, Muzyczka N, Baker TS, Agbandje-McKenna M. Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol. 2012 86:6947-58.

Doerfler PA, Byrne BJ, Clément N. Copackaging of multiple adeno-associated viral vectors in a single production step. Hum Gene Ther Methods. 2014 25:269-76.

Halder S, Van Vliet K, Smith JK, Duong TT, McKenna R, Wilson JM, Agbandje-McKenna M. Structure of neurotropic adeno-associated virus AAVrh.8. J Struct Biol. 2015 192:21-36.

Higuchi M, Haginoya K, Yamazaki T, Miyamoto K, Katagiri T, Tomimoto K, Shitomi Y, Hayakawa T, Sato R, Hori H. Binding of Bacillus thuringiensis Cry1A toxins to brush border membrane vesicles of midgut from Cry1Ac susceptible and resistant Plutella xylostella. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology 2007 147: 716–724.

Hori Y, Hashimoto T, Nomoto H, Hyman BT, Iwatsubo T. Role of Apolipoprotein E in β-Amyloidogenesis: Isoform-Specific Effects on Protofibril to Fibril Conversion of Aβ in vitro and Brain Aβ Deposition in vivo. J Biol Chem. 2015 290:15163-7.

Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, Ochiai T. Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Science 2006 97:380-386.

Mahajan MC, Narlikar GJ, Boyapaty G, Kingston RE, Weissman SM. Heterogeneous nuclear ribonucleoprotein C1/C2, MeCP1, and SWI/SNF form a chromatin remodeling complex at the beta-globin locus control region. Proc Natl Acad Sci U S A. 2005 102:15012-7.

Méndez-Gómez, H. R., Galera-Prat, A., Meyers, C., Chen, W., Singh, J., Carrión-Vázquez, M., & Muzyczka, N. Transcytosis in the blood–cerebrospinal fluid barrier of the mouse brain with an engineered receptor/ligand system. Molecular Therapy. Methods & Clinical Development 2015 2, 15037.

Okai M, Kudo N, Lee WC, Kamo M, Nagata K, Tanokura M. Crystal structures of the short-chain flavin reductase HpaC from Sulfolobus tokodaii strain 7 in its three states: NAD(P)( )(-) free, NAD( )(-) bound, and NADP( )(-) bound. Biochemistry. 2006 45:5103-10.

Pandya J, Ortiz L, Ling C, Rivers A & Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunology and Cell Biology 2014 92, 116–123.

Reddy VB, Iuga AO, Kounga K, Lerner EA. Functional analysis of recombinant mutants of maxadilan with a PAC1 receptor-expressing melanophore cell line. J Biol Chem. 2006 281:16197-201.

Reisz JA, Zink CN, King SB. Rapid and selective nitroxyl (HNO) trapping by phosphines: kinetics and new aqueous ligations for HNO detection and quantitation. J Am Chem Soc. 2011 133:11675-85.

Sayroo R, Nolasco D, Yin Z, Colon-Cortes Y, Pandya M, Ling C, Aslanidi G. Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 2016 23:18-25.

Tsunetsugu-Yokota Y, Ato M, Takahashi Y, Hashimoto S, Kaji T , Kuraoka M, Yamamoto K, Mitsuki Y, Yamamoto T, Oshima M, Ohnishi K & Takemori T. Formalin-Treated UV-Inactivated SARS Coronavirus Vaccine Retains Its Immunogenicity and Promotes Th2-Type Immune Responses. Jpn. J. Infect. Dis. 2007 60: 106-112.

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.